Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 605

1.

Response to Fungal Dysbiosis by Gut-Resident CX3CR1+ Mononuclear Phagocytes Aggravates Allergic Airway Disease.

Li X, Leonardi I, Semon A, Doron I, Gao IH, Putzel GG, Kim Y, Kabata H, Artis D, Fiers WD, Ramer-Tait AE, Iliev ID.

Cell Host Microbe. 2018 Dec 12;24(6):847-856.e4. doi: 10.1016/j.chom.2018.11.003. Epub 2018 Nov 29.

PMID:
30503509
2.

Structural Basis of Polyketide Synthase O-Methylation.

Skiba MA, Bivins MM, Schultz JR, Bernard SM, Fiers WD, Dan Q, Kulkarni S, Wipf P, Gerwick WH, Sherman DH, Aldrich CC, Smith JL.

ACS Chem Biol. 2018 Dec 21;13(12):3221-3228. doi: 10.1021/acschembio.8b00687. Epub 2018 Dec 3.

PMID:
30489068
3.

Oral delivery of Escherichia coli persistently infected with M2e-displaying bacteriophages partially protects against influenza A virus.

Deng L, Roose K, Job ER, De Rycke R, Van Hamme E, Gonçalves A, Parthoens E, Cicchelero L, Sanders N, Fiers W, Saelens X.

J Control Release. 2017 Oct 28;264:55-65. doi: 10.1016/j.jconrel.2017.08.020. Epub 2017 Aug 24.

PMID:
28842314
4.

Teixobactin and Its Analogues: A New Hope in Antibiotic Discovery.

Fiers WD, Craighead M, Singh I.

ACS Infect Dis. 2017 Oct 13;3(10):688-690. doi: 10.1021/acsinfecdis.7b00108. Epub 2017 Aug 3.

PMID:
28770988
5.

M2e-tetramer-specific memory CD4 T cells are broadly protective against influenza infection.

Eliasson DG, Omokanye A, Schön K, Wenzel UA, Bernasconi V, Bemark M, Kolpe A, El Bakkouri K, Ysenbaert T, Deng L, Fiers W, Saelens X, Lycke N.

Mucosal Immunol. 2018 Jan;11(1):273-289. doi: 10.1038/mi.2017.14. Epub 2017 Mar 1.

PMID:
28295019
6.

Synthesis of Transition-State Inhibitors of Chorismate Utilizing Enzymes from Bromobenzene cis-1,2-Dihydrodiol.

Zhang XK, Liu F, Fiers WD, Sun WM, Guo J, Liu Z, Aldrich CC.

J Org Chem. 2017 Apr 7;82(7):3432-3440. doi: 10.1021/acs.joc.6b02801. Epub 2017 Mar 17.

7.

Bispecific T cell engaging antibody constructs targeting a universally conserved part of the viral M2 ectodomain cure and prevent influenza A virus infection.

Pendzialek J, Roose K, Smet A, Schepens B, Kufer P, Raum T, Baeuerle PA, Muenz M, Saelens X, Fiers W.

Antiviral Res. 2017 May;141:155-164. doi: 10.1016/j.antiviral.2017.02.016. Epub 2017 Mar 1.

PMID:
28257797
8.

Vinylogous Dehydration by a Polyketide Dehydratase Domain in Curacin Biosynthesis.

Fiers WD, Dodge GJ, Sherman DH, Smith JL, Aldrich CC.

J Am Chem Soc. 2016 Dec 14;138(49):16024-16036. Epub 2016 Nov 30.

9.

Domain Organization and Active Site Architecture of a Polyketide Synthase C-methyltransferase.

Skiba MA, Sikkema AP, Fiers WD, Gerwick WH, Sherman DH, Aldrich CC, Smith JL.

ACS Chem Biol. 2016 Dec 16;11(12):3319-3327. Epub 2016 Oct 18.

10.

M2-based influenza vaccines: recent advances and clinical potential.

Kolpe A, Schepens B, Fiers W, Saelens X.

Expert Rev Vaccines. 2017 Feb;16(2):123-136. doi: 10.1080/14760584.2017.1240041. Epub 2016 Oct 5. Review.

PMID:
27653543
11.

Long-Lasting Cross-Protection Against Influenza A by Neuraminidase and M2e-based immunization strategies.

Schotsaert M, Ysenbaert T, Smet A, Schepens B, Vanderschaeghe D, Stegalkina S, Vogel TU, Callewaert N, Fiers W, Saelens X.

Sci Rep. 2016 Apr 13;6:24402. doi: 10.1038/srep24402.

12.

Crystal Structure of the Conserved Amino Terminus of the Extracellular Domain of Matrix Protein 2 of Influenza A Virus Gripped by an Antibody.

Cho KJ, Schepens B, Moonens K, Deng L, Fiers W, Remaut H, Saelens X.

J Virol. 2015 Oct 14;90(1):611-5. doi: 10.1128/JVI.02105-15. Print 2016 Jan 1.

13.
14.

M2e-Based Universal Influenza A Vaccines.

Deng L, Cho KJ, Fiers W, Saelens X.

Vaccines (Basel). 2015 Feb 13;3(1):105-36. doi: 10.3390/vaccines3010105. Review.

15.

Functional Comparison of Mx1 from Two Different Mouse Species Reveals the Involvement of Loop L4 in the Antiviral Activity against Influenza A Viruses.

Verhelst J, Spitaels J, Nürnberger C, De Vlieger D, Ysenbaert T, Staeheli P, Fiers W, Saelens X.

J Virol. 2015 Nov;89(21):10879-90. doi: 10.1128/JVI.01744-15. Epub 2015 Aug 19.

16.

Functional Characterization of a Dehydratase Domain from the Pikromycin Polyketide Synthase.

Li Y, Dodge GJ, Fiers WD, Fecik RA, Smith JL, Aldrich CC.

J Am Chem Soc. 2015 Jun 10;137(22):7003-6. doi: 10.1021/jacs.5b02325. Epub 2015 Jun 2.

17.

Protection against Influenza A Virus Challenge with M2e-Displaying Filamentous Escherichia coli Phages.

Deng L, Ibañez LI, Van den Bossche V, Roose K, Youssef SA, de Bruin A, Fiers W, Saelens X.

PLoS One. 2015 May 14;10(5):e0126650. doi: 10.1371/journal.pone.0126650. eCollection 2015.

18.

A GFP expressing influenza A virus to report in vivo tropism and protection by a matrix protein 2 ectodomain-specific monoclonal antibody.

De Baets S, Verhelst J, Van den Hoecke S, Smet A, Schotsaert M, Job ER, Roose K, Schepens B, Fiers W, Saelens X.

PLoS One. 2015 Mar 27;10(3):e0121491. doi: 10.1371/journal.pone.0121491. eCollection 2015.

19.

Structure of the extracellular domain of matrix protein 2 of influenza A virus in complex with a protective monoclonal antibody.

Cho KJ, Schepens B, Seok JH, Kim S, Roose K, Lee JH, Gallardo R, Van Hamme E, Schymkowitz J, Rousseau F, Fiers W, Saelens X, Kim KH.

J Virol. 2015 Apr;89(7):3700-11. doi: 10.1128/JVI.02576-14. Epub 2015 Jan 21.

20.

Polyketide intermediate mimics as probes for revealing cryptic stereochemistry of ketoreductase domains.

Li Y, Fiers WD, Bernard SM, Smith JL, Aldrich CC, Fecik RA.

ACS Chem Biol. 2014 Dec 19;9(12):2914-22. doi: 10.1021/cb5006883. Epub 2014 Nov 5.

21.

Protection and mechanism of action of a novel human respiratory syncytial virus vaccine candidate based on the extracellular domain of small hydrophobic protein.

Schepens B, Sedeyn K, Vande Ginste L, De Baets S, Schotsaert M, Roose K, Houspie L, Van Ranst M, Gilbert B, van Rooijen N, Fiers W, Piedra P, Saelens X.

EMBO Mol Med. 2014 Nov;6(11):1436-54. doi: 10.15252/emmm.201404005.

22.

Single-domain antibodies targeting neuraminidase protect against an H5N1 influenza virus challenge.

Cardoso FM, Ibañez LI, Van den Hoecke S, De Baets S, Smet A, Roose K, Schepens B, Descamps FJ, Fiers W, Muyldermans S, Depicker A, Saelens X.

J Virol. 2014 Aug;88(15):8278-96. doi: 10.1128/JVI.03178-13. Epub 2014 May 14.

23.

Immunogenicity of live attenuated B. pertussis BPZE1 producing the universal influenza vaccine candidate M2e.

Kammoun H, Roux X, Raze D, Debrie AS, De Filette M, Ysenbaert T, Mielcarek N, Saelens X, Fiers W, Locht C.

PLoS One. 2013;8(3):e59198. doi: 10.1371/journal.pone.0059198. Epub 2013 Mar 19.

24.

M2e-displaying virus-like particles with associated RNA promote T helper 1 type adaptive immunity against influenza A.

Ibañez LI, Roose K, De Filette M, Schotsaert M, De Sloovere J, Roels S, Pollard C, Schepens B, Grooten J, Fiers W, Saelens X.

PLoS One. 2013;8(3):e59081. doi: 10.1371/journal.pone.0059081. Epub 2013 Mar 18.

25.

Recombinant influenza virus carrying the respiratory syncytial virus (RSV) F85-93 CTL epitope reduces RSV replication in mice.

De Baets S, Schepens B, Sedeyn K, Schotsaert M, Roose K, Bogaert P, Fiers W, Saelens X.

J Virol. 2013 Mar;87(6):3314-23. doi: 10.1128/JVI.03019-12. Epub 2013 Jan 9.

26.

Interferon-inducible protein Mx1 inhibits influenza virus by interfering with functional viral ribonucleoprotein complex assembly.

Verhelst J, Parthoens E, Schepens B, Fiers W, Saelens X.

J Virol. 2012 Dec;86(24):13445-55. doi: 10.1128/JVI.01682-12. Epub 2012 Sep 26.

27.

Natural and long-lasting cellular immune responses against influenza in the M2e-immune host.

Schotsaert M, Ysenbaert T, Neyt K, Ibañez LI, Bogaert P, Schepens B, Lambrecht BN, Fiers W, Saelens X.

Mucosal Immunol. 2013 Mar;6(2):276-87. doi: 10.1038/mi.2012.69. Epub 2012 Jul 18.

PMID:
22806098
28.

Cytokine research in Belgium.

Fiers W.

Cytokine Growth Factor Rev. 2011 Oct-Dec;22(5-6):255-6. doi: 10.1016/j.cytogfr.2011.11.008. No abstract available.

PMID:
22152225
29.

A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus.

Eliasson DG, Helgeby A, Schön K, Nygren C, El-Bakkouri K, Fiers W, Saelens X, Lövgren KB, Nyström I, Lycke NY.

Vaccine. 2011 May 23;29(23):3951-61. doi: 10.1016/j.vaccine.2011.03.090. Epub 2011 Apr 8.

PMID:
21481325
30.

Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection.

El Bakkouri K, Descamps F, De Filette M, Smet A, Festjens E, Birkett A, Van Rooijen N, Verbeek S, Fiers W, Saelens X.

J Immunol. 2011 Jan 15;186(2):1022-31. doi: 10.4049/jimmunol.0902147. Epub 2010 Dec 17.

31.

Antiserum against the conserved nine amino acid N-terminal peptide of influenza A virus matrix protein 2 is not immunoprotective.

De Filette M, Ysenbaert T, Roose K, Schotsaert M, Roels S, Goossens E, Schepens B, Fiers W, Saelens X.

J Gen Virol. 2011 Feb;92(Pt 2):301-6. doi: 10.1099/vir.0.027086-0. Epub 2010 Oct 21.

PMID:
20965983
32.

Controlling influenza by cytotoxic T-cells: calling for help from destroyers.

Schotsaert M, Ibañez LI, Fiers W, Saelens X.

J Biomed Biotechnol. 2010;2010:863985. doi: 10.1155/2010/863985. Epub 2010 May 24.

33.

M2e-based universal influenza A vaccine.

Fiers W, De Filette M, El Bakkouri K, Schepens B, Roose K, Schotsaert M, Birkett A, Saelens X.

Vaccine. 2009 Oct 23;27(45):6280-3. doi: 10.1016/j.vaccine.2009.07.007. Review.

PMID:
19840661
34.

Cloning and expression of human interferon-beta: from bc to ac.

Fiers W.

Verh K Acad Geneeskd Belg. 2009;71(1-2):43-50. Review.

PMID:
19739397
35.

Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments.

Schotsaert M, De Filette M, Fiers W, Saelens X.

Expert Rev Vaccines. 2009 Apr;8(4):499-508. doi: 10.1586/erv.09.6. Review.

36.

Pandemic preparedness: toward a universal influenza vaccine.

Roose K, Fiers W, Saelens X.

Drug News Perspect. 2009 Mar;22(2):80-92. doi: 10.1358/dnp.2009.22.2.1334451. Review.

PMID:
19330167
37.

Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies.

De Filette M, Martens W, Smet A, Schotsaert M, Birkett A, Londoño-Arcila P, Fiers W, Saelens X.

Vaccine. 2008 Dec 2;26(51):6503-7. doi: 10.1016/j.vaccine.2008.09.038.

PMID:
18835315
38.

An influenza A vaccine based on tetrameric ectodomain of matrix protein 2.

De Filette M, Martens W, Roose K, Deroo T, Vervalle F, Bentahir M, Vandekerckhove J, Fiers W, Saelens X.

J Biol Chem. 2008 Apr 25;283(17):11382-7. doi: 10.1074/jbc.M800650200. Epub 2008 Feb 5.

39.

CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine.

Eliasson DG, El Bakkouri K, Schön K, Ramne A, Festjens E, Löwenadler B, Fiers W, Saelens X, Lycke N.

Vaccine. 2008 Feb 26;26(9):1243-52. doi: 10.1016/j.vaccine.2007.12.027. Epub 2008 Jan 10.

PMID:
18243429
40.

A universal vaccine against influenza.

Fiers W.

Bull Mem Acad R Med Belg. 2006;161(5):237-9. No abstract available.

PMID:
17283895
41.

Improved design and intranasal delivery of an M2e-based human influenza A vaccine.

De Filette M, Fiers W, Martens W, Birkett A, Ramne A, Löwenadler B, Lycke N, Jou WM, Saelens X.

Vaccine. 2006 Nov 10;24(44-46):6597-601. Epub 2006 Jun 12.

PMID:
16814430
42.

The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection.

De Filette M, Ramne A, Birkett A, Lycke N, Löwenadler B, Min Jou W, Saelens X, Fiers W.

Vaccine. 2006 Jan 30;24(5):544-51. Epub 2005 Aug 31.

PMID:
16169634
43.

Universal influenza A vaccine: optimization of M2-based constructs.

De Filette M, Min Jou W, Birkett A, Lyons K, Schultz B, Tonkyro A, Resch S, Fiers W.

Virology. 2005 Jun 20;337(1):149-61.

44.

A "universal" human influenza A vaccine.

Fiers W, De Filette M, Birkett A, Neirynck S, Min Jou W.

Virus Res. 2004 Jul;103(1-2):173-6. Review.

PMID:
15163506
45.

Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil) correlates with altered Doxil pharmacokinetics.

Brouckaert P, Takahashi N, van Tiel ST, Hostens J, Eggermont AM, Seynhaeve AL, Fiers W, ten Hagen TL.

Int J Cancer. 2004 Apr 10;109(3):442-8.

46.

Bioavailability of recombinant tumor necrosis factor determines its lethality in mice.

Ameloot P, Takahashi N, Everaerdt B, Hostens J, Eugster HP, Fiers W, Brouckaert P.

Eur J Immunol. 2002 Oct;32(10):2759-65.

47.

Cloning and Expression of a Fused Gene Encoding TNFRI Death Domain and Chloramphenicol Acetyltransferase.

Lin LZ, Li CB, Zhao SY, De Wilde G, Haegeman G, Fiers W.

Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 1998;30(6):597-600.

PMID:
12167995
48.

Characterization of the interaction between murine tumour necrosis factor and monoclonal antibodies.

Ameloot P, Fiers W, Buurman WA, de Baetselier P, Brouckaert P.

Cytokine. 2002 May 7;18(3):158-63.

PMID:
12126652
49.

Soluble recombinant influenza vaccines.

Fiers W, Neirynck S, Deroo T, Saelens X, Jou WM.

Philos Trans R Soc Lond B Biol Sci. 2001 Dec 29;356(1416):1961-3. Review.

50.

Expression in Escherichia coli of the death domain of the human p55 tumor necrosis factor receptor.

De Wilde G, Mertens N, Boone E, De Vreese B, Van Beeumen J, Fiers W, Haegeman G.

Protein Expr Purif. 2001 Nov;23(2):226-32.

PMID:
11676596

Supplemental Content

Support Center